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1. 
BOMARKERS USED TO DETECT AND 
MONITORNEUROLOGICAL AUTOMMUNE 
DISEASES 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims the priority of benefit to U.S. appli 
cation Ser. No. 61/680,938 filed on Aug. 8, 2012. The previ 
ous application is incorporated herein in its entirety. 
FEDERALLY SPONSORED RESEARCHOR 
DEVELOPMENT 
This invention was made with government Support under 
Grant Nos. R21 AI081154, RRO15468, and P20 RR017675 
awarded by the National Institutes of Health. The government 
has certain rights in the invention. 
TECHNICAL FIELD 
This disclosure generally relates to biomarkers for neuro 
logical autoimmune diseases and methods of using Such 
biomarkers. 
BACKGROUND 
Autoimmune diseases arise from an inappropriate immune 
response by the body against Substances or tissues normally 
found in the body. Neurological autoimmune diseases are 
those autoimmune diseases that affect some aspect of the 
neurological system (e.g., the central nervous system or the 
peripheral nervous system). Biomarkers of one or more neu 
rological autoimmune diseases, especially those biomarkers 
that can be evaluated non-invasively, are useful in the art. 
SUMMARY 
Biomarkers of neurological autoimmune diseases are pro 
vided, and methods of using Such biomarkers also are pro 
vided. 
In one aspect, a method of determining if a patient is 
Suffering from, or is at risk of Suffering from, a neurological 
autoimmune disease is provided. Such a method includes 
collecting a urine sample from a patient; and determining the 
levels of one or more biomarkers in the patient’s urine, 
wherein the one or more biomarkers are selected from the 
group consisting of 3-ureidopropionic acid, guanidinoacetate 
and indoxyl sulfate. Generally, an increase in the level of the 
one or more biomarkers in the patient’s urine is indicative of 
the presence of a neurological autoimmune disease in the 
patient. A representative neurological autoimmune disease is 
multiple Sclerosis. 
In some embodiments, the biomarkers are 3-ureidopropi 
onic acid and guanidinoacetate. In some embodiments, the 
biomarkers are 3-ureidopropionic acid and indoxyl Sulfate. In 
Some embodiments, the biomarkers are guanidinoacetate and 
indoxyl Sulfate. In some embodiments, the biomarkers are 
3-ureidopropionic acid, guanidinoacetate and indoxyl Sul 
fate. The levels of the one or more biomarkers can be deter 
mined, for example, using an immunoassay, chromatography, 
spectroscopy or NMR. 
In some embodiments, the levels of the one or more biom 
arkers in the patient’s urine are compared to the levels of the 
one or more biomarkers in a control patient that does not 













embodiments, the levels of the one or more biomarkers in the 
patient’s urine are compared to a standardized control. 
In another aspect, a method of determining whether a com 
pound is effective for treating a Subject having a neurological 
autoimmune disease is provided. Such a method typically 
includes collecting a first urine sample from a Subject; deter 
mining the levels of one or more biomarkers in the first urine 
sample, wherein the one or more biomarkers are selected 
from the group consisting of 3-ureidopropionic acid, guani 
dinoacetate and indoxyl Sulfate; administering a compound to 
the Subject; collecting a second urine sample from the Sub 
ject; and determining the levels of one or more of the biom 
arkers in the secondurine sample. Generally, a decrease in the 
level of one or more biomarkers in the secondurine sample 
relative to the first urine sample is indicative of a compound 
that is effective for treating a subject having a neurological 
autoimmune disease. In one embodiment, the neurological 
autoimmune disease is multiple Sclerosis. 
In some instances, the Subject is a non-human animal. In 
Some instances, the Subject is a human. 
In some embodiments, the biomarkers are 3-ureidopropi 
onic acid and guanidinoacetate. In some embodiments, the 
biomarkers are 3-ureidopropionic acid and indoxyl Sulfate. In 
Some embodiments, the biomarkers are guanidinoacetate and 
indoxyl Sulfate. In some embodiments, the biomarkers are 
3-ureidopropionic acid, guanidinoacetate and indoxyl Sul 
fate. The levels of the one or more biomarkers can be deter 
mined, for example, using an immunoassay, chromatography, 
spectroscopy or NMR. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which the methods and 
compositions of matter belong. Although methods and mate 
rials similar or equivalent to those described herein can be 
used in the practice or testing of the methods and composi 
tions of matter, suitable methods and materials are described 
below. In addition, the materials, methods, and examples are 
illustrative only and not intended to be limiting. All publica 
tions, patent applications, patents, and other references men 
tioned herein are incorporated by reference in their entirety. 
DESCRIPTION OF DRAWINGS 
Part A: Preliminary Experiments and Results 
FIG. 1A shows the urine metabolites that are upregulated/ 
downregulated in EAE mice. EAE was induced in C57B1/6 
mice using MOG 35-55 in CFA and urine samples were 
obtained from EAE mice that scored 3 to 4 and age-matched 
healthy mice on day 17 post-immunization. The samples 
were subjected to 2D 1H-13C HSQC NMR spectroscopy 
analysis and the data were analyzed to compare the compo 
sition of metabolites in EAE versus the control as described 
herein. The urine metabolites are represented on the x-axis 
and the fold difference on the y-axis. The metabolites with a 
positive difference are those that have a greater presence in 
EAE mice, and the metabolites with a negative difference are 
those that have a greater presence in control mice. FIGS. 
1(B)-(G) are graphs showing the overall results broken down 
by organic acids (FIG. 1B), amino acids (FIG. 1C), carbohy 
drates (FIG.1D), microbial products (FIG.1E), amines (FIG. 
1F), and alcohols, ketones and aldehydes (FIG. 1G). 
FIG. 2 is a schematic showing the metabolite pathway 
network developed from the results shown in FIG. 1. 
Part B: NMR Metabolomics-Based Analysis of Urine 
FIG. 3 is a graph showing the 1D H-NMR spectrum of 
healthy, diseased and treated mice. 
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FIG.4, Panel (A) is the 2DOPLS-DA score plot analysis of 
healthy (dark Square), Saline injected (5-point star), CFA 
injected (dark pentagon), diseased (large Sun-shaped star), 
healthy treated with fingolimod (light square), CFA injected 
mice treated with fingolimod (light circle), and diseased mice 
treated with fingolimod (dark circle). Panel (B) is a metabo 
lomics tree diagram based on the 2D OPLS-DA score plot of 
Panel (A). 
FIG. 5 is an OPLS-DA S-plot for urine collected from 
healthy, saline-injected, CFA-injected, EAE mice (diseased), 
healthy mice treated with Fingolimod, CFA-injected mice 
treated with Fingolimod, and diseased mice treated with Fin 
golimod. 
FIG. 6 is a bar graph of metabolites up- or down-regulated 
in the urine of EAE mice. GA (guanidoacetic acid), OA 
(oxoglutaric acid), UN2 (unknown 2), ISU (indoxylsulfate), 
UDPA (ureidopropionic acid), MG (methylguanidine), NGA 
(N-acetylglutamic acid), PA (pimelic acid), NAP 
(N-acetylputrescine), GAD (glyceraldehyde), NAK (N6 
acetylysine), TMA (trimethylamine), AGM (agmatine), 
MET (methionine), and UN1 (unknown 1). 
Like reference symbols in the various drawings indicate 
like elements. 
DETAILED DESCRIPTION 
Neurological autoimmune diseases such as multiple scle 
rosis (MS) are very challenging diseases to properly diag 
nose, and misdiagnosis is common. The diagnosis of MS 
typically uses the McDonald criteria (McDonald et al., 2001, 
Ann. Neurol., 50:121-7. Polman et al., 2005, Ann. Neurol., 
58:840-6), which relies on history, magnetic resonance imag 
ing, visual evoked potentials, cerebrospinal fluid analysis and 
hematology. Significant effort has been employed to identify 
biomarkers from cerebrospinal fluid (CSF) to facilitate a 
diagnosis for MS, but this endeavor has proven to be 
extremely challenging and has not been Successful to date. 
Additionally, there are associated risks with obtaining CSF 
from patients. Therefore, a study was undertaken to investi 
gate whether urine metabolites could be used as biomarkers 
of MS and to evaluate the in vivo activity of MS drugs, given 
that urine can be obtained non-invasively. 
Three different metabolites were identified in urine, each 
of which can be used as a biomarker to detect or diagnose a 
neurological autoimmune disease such as MS in a patient 
Suspected of Suffering from Such a disease, or at risk of 
suffering from such a disease. Similarly, any of the three 
biomarkers identified hereincan be used to evaluate the effec 
tiveness or efficacy of a compound (e.g., a drug) for treating 
Such a disease. 
One of the biomarkers, indoxyl sulfate (Human Metabo 
lome Database (HMDB) 00682), is a dietary protein metabo 
lite and also is a metabolite of the amino acid, tryptophan. In 
addition, indoxyl Sulfate strongly decreases the levels of glu 
tathione, which is one of the most active antioxidant systems 
of the cell. The other biomarkers, guanidinoacetate (HMDB 
00128) and 3-ureidopropionic acid (HMDB 00026), are inter 
mediates in the metabolism of amino acids and nucleic acids, 
respectively, and have been shown to be associated with neu 
rological diseases (Kolker et al., 2001, J. Neurosci. Res., 
66:666-673; Neu et al., 2002, Neurobiol. Dis., 11:298–307), 
but not necessarily neurological diseases with an autoim 
mune component. All three biomarkers are statistically sig 
nificantly down-regulated in an animal model of Suffering 
from a neurological autoimmune disease similar to MS. 
Animals having an existing or induced disease or injury 














research as animal models. Those skilled in the art would 
appreciate that rats, mice, guinea pigs, rabbits, and monkeys 
can be induced to exhibit Experimental Autoimmune 
Encephalomyelitis (EAE), which results in an animal model 
exhibiting an autoimmune disease characterized by inflam 
mation and demyelination of the central nervous system 
(CNS) (Gold et al., 2006, Brain, 129:1953-71; Miller et al., 
2007, Curr: Prot. Immunol., Ch 15, Unit 15.1). EAE is con 
sidered to be an animal model of MS because it exhibits 
delayed onset; chronic-progressive course; relapsing-course; 
and widespread lesions. See, for example, Steinman et al., 
2005, Trends Immunol., 26:565-71; and Steinman & Zamvil, 
2006, Ann. Neurol., 60:12-21. While the methods described 
herein can be used in the diagnosis and evaluation of MS, the 
methods described herein also can be used in the diagnosis 
and evaluation of symptoms associated with other neurologi 
cal autoimmune diseases. 
Thus, determining the level of one or more of these biom 
akers in urine can be used to determine if a patient is Suffering 
from or is at risk of suffering from a neurological autoimmune 
disease. As described herein, a decrease (e.g., a statistically 
significant decrease) in the level of one, two or three of the 
biomarkers (e.g., 3-ureidopropionic acid, guanidinoacetate, 
or indoxyl Sulfate; 3-ureidopropionic acid & guanidinoac 
etate, 3-ureidopropionic acid & indoxyl Sulfate, or guanidi 
noacetate & indoxyl Sulfate; or 3-ureidopropionic acid, 
guanidinoacetate & indoxyl Sulfate) indicates the presence of 
a neurological autoimmune disease (e.g., MS) in the patient. 
As used herein, statistical significance refers to a p-value of 
less than 0.05, e.g., a p-value of less than 0.025 or a p-value of 
less than 0.01, using an appropriate measure of statistical 
significance, e.g., a one-tailed two sample t-test. 
It would be appreciated by those in the art that the levels of 
the one or more biomarkers in the urine from a patient can be 
compared to a control in order to determine whether or not 
there is a decrease in the levels of one or more of the biom 
arkers in the patient. A control can be a sample from a control 
patient that does not suffer from a neurological autoimmune 
disease or from MS in which the level of the respective 
biomarker(s) is determined. Additionally or alternatively, a 
control can refer to a number or range of numbers that has 
been standardized to the level of the respective biomarker(s) 
in one or more control patients or a control population. 
The methods described herein also can be used to deter 
mine whether or not a compound is effective for treating a 
Subject having a neurological autoimmune disease. For 
example, urine can be collected at least one time before (e.g., 
a first urine sample) and at least one time after (e.g., a second 
urine sample) a compound is administered to a subject. A 
change in the level of a biomarker refers to the difference 
between the level of the biomarker in the secondurine sample 
and the level of the biomarker in the first urine sample and can 
be expressed as the lack of a decrease in the level of the 
biomarker (e.g., an increase or no change in the level of the 
biomarker) or a decrease in the level of the biomarker. 
In some embodiments, the Subject being administered the 
compound is a human patient that is receiving a pharmaceu 
tical composition (e.g., a drug), and the methods can be used 
to monitor and evaluate the response of the patient to the 
compound. For example, an increase in the level of any of the 
biomarkers identified herein in the secondurine sample over 
the first urine sample is an indication that the compound is 
effective for treating a neurological autoimmune disease Such 
as MS. On the other hand, a decrease in the level of any of the 
biomarkers identified herein in the secondurine sample over 
US 9,304,123 B2 
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the first urine sample is an indication that the compound is not 
effective for treating a neurological autoimmune disease Such 
as MS. 
In some embodiments, the Subject being administered the 
compound can be a non-human animal (e.g., an animal 
model, e.g., an EAE animal or a NOD mouse). A subject can 
be administered a compound (e.g., a test compound) and the 
level of one or more of the biomarkers described hereincan be 
determined. These methods can be used, for example, to 
screen compounds for their effectiveness in treating a subject 
having a neurological autoimmune disease. As indicated 
above, the lack of a decrease in the level of any of the biom 
arkers identified herein in the second urine sample over the 
first urine sample is an indication that the compound may be 
effective for treating a neurological autoimmune disease 
(e.g., MS), while a decrease in the level of any of the biom 
arkers identified herein in the second urine sample over the 
first urine sample is an indication that the compound likely is 
not effective for treating a neurological autoimmune disease 
(e.g., MS). 
Compounds (e.g., test compounds) include, without limi 
tation, nucleic acids (e.g., oligonucleotides), polypeptides 
(e.g., enzymes, antibodies), chemical compounds, extracts 
from bacteria, plant, fungi or animal cells, or mixtures 
thereof. Such compounds can be administered to a subject 
using any known means including, but not limited to, orally, 
intravenously, intramuscularly, intraperitoneally, Subcutane 
ously, intradermally, or topically. 
As used herein, a compound that is effective for “treating 
a patient or a subject refers to a compound that manages, 
alleviates, ameliorates or remediates one or more symptoms 
associated with a neurological autoimmune disease. The 
symptoms associated with neurological autoimmune dis 
eases are vastand include, simply by way of example, blurred 
or loss of vision, loss of coordination, loss of balance, loss of 
bladder control, sexual dysfunction, fatigue, fever, numbness, 
tingling and/or weakness of extremities, joint and/or muscle 
aches, weight loss, hair loss, skin rash, and combinations 
thereof. 
Methods of collecting or expressing urine samples from 
human patients or from animal Subjects are well known in the 
art, as are methods of handling and storing urine samples. 
The biomarkers described herein can be detected in urine 
using any number of methods. For example, immunoassays 
are well known in the art and include, without limitation, 
enzyme-linked immunosorbent assays (ELISAS), radioim 
munoassays, Surround optical fiber immunoassay (SOFIA), 
cloned enzyme donor immunoassay (CEDIA), or magnetic 
immunoassay (MIA). The biomarkers described herein also 
can be detected using, for example, liquid-chromatography 
mass spectrometry (LC-MS); gas-chromatography-mass 
spectrometry (GC-MS), liquid-chromatography-electro 
chemistry array metabolomics platforms (LCECA), fourier 
transform infrared spectroscopy (FTIR), capillary electro 
phoresis electrospray ionization mass spectrometry (CE-ESI 
MS), and ultra-performance liquid chromatography mass 
spectrometry (UPLC-MS). In addition and as described 
herein, the biomarkers can be detected in urine using NMR 
(e.g., 1-dimensional (1D) or 2-dimensional (2D) NMR). 
In accordance with the present invention, there may be 
employed conventional molecular biology, microbiology, 
biochemical, and recombinant DNA techniques within the 
skill of the art. Such techniques are explained fully in the 













lowing examples, which do not limit the scope of the methods 
and compositions of matter described in the claims. 
EXAMPLES 
Part A: Preliminary Experiments and Results 
Example 1 
Sample Preparation 
Groups of 5-to 6-week old female C57B 1/6 mice were 
immunized with or without MOG 35-55 (MEVGWYRSPFS 
RVVHLYRNGK (SEQ ID NO:1)) in complete Freund's 
adjuvant (CFA; 200 ug/mouse) subcutaneously as described 
(n=13 each) (Miller et al., 2007, Curr. Protoc. Immunol. Ch 
15, Unit 15 11: Mendel et al., 1995, Eur: J. Immunol., 
25:1951-9). The animals were monitored for clinical signs of 
EAE and scored until termination, which occurred on day 30 
post-immunization (Miller et al., Supra; Mendel et al., Supra). 
Urine samples were collected daily starting day -1 until day 
30 from controls and mice with EAE showing bilateral hind 
limb paralysis (scored 4). Three sample pools of 500 ul were 
prepared for each group of mice and the Volumes were 
brought up to 600 ul by adding 100 ul deuterium oxide (pH of 
7.2) prior to NMR analysis. 
Example 2 
Sample Analysis 
NMR experiments were conducted on urine samples col 
lected from controls and EAE mice using Bruker AVANCE 
DRX 500 MHz spectrometer equipped with 5 mm Triple 
resonance Cryoprobe (H, C, "N) with a Z-axis gradient. 
The 2D 'H-'C HSQC NMR data was collected using the 
following parameters: 512 scans, 32 dummy Scan, 1.5 S relax 
ation delay and with 64 fid size. All the spectra were pro 
cessed using NMRPipe (see, for example, spinniddk.nih 
.gov/NMRPipe?) and peak matching, and peak assignments 
were performed using NMRView.J. Version 8.0 (see, for 
example, the World Wide Web at onemoonscientific.com/ 
nmrview/summary.html) and chemical shift references from 
the Human Metabolomics Database (HMDB) (see, for 
example, hmdb.ca on the World Wide Web). The urinary 
metabolites that are differentially excreted in controls and 
EAE mice were noted and the metabolic intensities obtained 
in EAE mice were subtracted from those of control mice to 
determine fold-change for each metabolite. The data are pre 
sented in FIGS. 1 and 1A-1F. 
FIG. 2 shows the pathway information for each of the 
urinary metabolites that are differentially excreted in EAE 
mice, which were obtained from the Kyoto Encylopedia of 
Genes and Genomes (KEGG) (see, for example, genome.jp/ 
keg?kegg3a.html on the World Wide Web) and BioCyc (see 
for example, biocyc.org on the WorldWideWeb). The urinary 
metabolites were linked with the nearest possible metabolite 
in the pathway. 
Example 3 
Summary of Preliminary Experiments and Results 
The preliminary experiments above served to optimize the 
conditions for determining metabolites in urine. The prelimi 
nary results suggest that urine metabolites can be used to 
predict disease progression in CNS autoimmune diseases. In 
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addition, the urine metabolites can be used to evaluate the 
efficacy of one or more drugs. 




Six to eight-week-old female C57B1/6 (H-2) mice were 
obtained from the Jackson Laboratory (Bar Harbor, Me...). The 
mice were maintained in accordance with the animal protocol 
guidelines of the University of Nebraska-Lincoln, Lincoln, 
Nebr. 
Example 5 
Peptide Synthesis and Immunization Procedures 
MOG 35-55 peptide (SEQ ID NO:1) was synthesized on 
9-fluorenylmethyloxy-carbonyl chemistry (Neopeptide, 
Cambridge, Mass.) to a purity of more than 90% as verified by 
HPLC and mass spectroscopy. The peptide was dissolved in 
1 xPBS, and stored at -20°C. until use. 
Example 6 
Immunization and Treatment Procedures 
The experimental design consisted of seven treatment 
groups (n=13). These include control, Saline, complete Fre 
und's adjuvant (CFA) alone, EAE treatment (see below), 
saline plus drug (Fingolimod), CFA plus drug, and EAE plus 
drug. Each treatment group was divided into three batches, 
each containing 4, 4 and 5 animals, respectively. 
EAE treatment refers to the process of inducing experi 
mental autoimmune encephalomyelitis (EAE) in mice, which 
is a MS-like disease characterized by inflammation and 
demyelination of the CNS. To induce EAE, peptide emul 
sions were prepared by mixing MOG 35-55 (SEQID NO:1) 
in CFA containing Mycobacterium tuberculosis H37RA 
extract (Difco Laboratories, Detroit, Mich.) to a final concen 
tration of 5 mg/ml. Each animal received 200 ug of peptide 
emulsion Subcutaneously in the inguinal and sternal regions. 
In addition, Pertussis toxin (List Biological Laboratories, 
Campbell, Calif.) was administered (200ng per mouse) intra 
peritoneally on day 0 and day 2 post immunization (Massila 
many et al., 2010, J. Neuroimmunol., 219:17-24: Massila 
many et al., 2011, J. Neuroimmunol., 230: 95-104; 
Massilamany et al., 2011, BMC Immunol., 12:40). Seven 
days post-immunization or in the no-injection control, fin 
golimod was dissolved in normal saline to a working dilution 
of 0.2 mg/ml, and administered intraperitoneally into the 
animals corresponding to drug-treated groups as indicated 
above at 1 mg/kg body weight daily until day 30. 
Example 7 
Urine Collection 
Urine samples were collected both prior to and after dis 
ease induction. The urine collections occurred three times 
daily from each animal by expressing the bladder. The 
samples collected from each batch of animals were pooled on 













addition, the samples collected from individual animals on 
days 16, 23 and 30 post-immunization were preserved as 
separate aliquots. 
Example 8 
NMR Sample Preparation 
For the 2D 'H-CHSQC experiments, 100 uL of a 50 mM 
phosphate buffer in 99.8% DO (Isotec) at pH 7.2 (PBS, 
uncorrected) were added to each 500 uL urine sample to a 
final volume of 600 uL. For the 1D H NMR experiments, 600 
uL of PBS was added to 10 uL of urine. 
Example 9 
NMR Data Collection and Analysis 
NMR experiments were conducted with Bruker AVANCE 
DRX 500 MHz spectrometer equipped with 5 mm Triple 
resonance Cryoprobe (H, C, "N) with a Z-axis gradient. A 
BACS-120 sample changer with Bruker Icon software was 
used to automate the NMR data collection. The 1D H NMR 
data was collected at 298K with 32K data points, a spectrum 
width of 5483 Hz 128 scan and 16 dummy scans using an 
excitation sculpting pulse sequence. The 2D 'H-'C HSQC 
NMR data was collected at 298K with 512 scans, 32 dummy 
scan and a 1.5 S relaxation delay. The spectrum was collected 
with 2048K data points and a spectrum width of 4734 Hz in 
the direct dimension and 64 data points and a spectrum width 
of 18864 Hz, in the indirect dimension. 
1D H NMR spectra were processed with the ACD/1D 
NMR manager version 12.0 (Advanced Chemistry Develop 
ment, Inc.). After the residual water peaks were removed, 
intelligent binning was used to integrate each region with a 
bucket size of 0.025 ppm. The noise regions were removed by 
changing the value of the bins to zero. Each NMR spectrum 
was mean-centered and auto-scaled by the standard deviation 
(Zhang et al., 2011, J. Proteome Res., 10:3743-54). Principal 
component analysis (PCA), Orthogonal Partial List Square 
Discreet Analysis (OPLS-DA) and S-plot were generated 
using SIMCA P+12 (UMETRICS). The PCA2Tree software 
was used to make the tree diagram (Werth et al., 2010, Ana 
lytical Biochem., 399:56-63). 
The 2D 'H-'C HSQC spectra were processed using 
NMRPipe. Peak picking and peak matching were performed 
using NMRView.JVersion 8.0. Peak intensities were normal 
ized for each 2D NMR spectrum by dividing by the average 
peak intensity for a given spectrum. Each peak for each 
metabolite from each specific triplicate data set was further 
normalized by the maximum intensity of the metabolite and 
scaled to 100. The metabolite percent change was calculated 
relative to the EAE group. Chemical shift references from the 
Human Metabolomics Database were used to assign each 




Evidence is presented that the NMR spectrum of urinary 
metabolites can be used to diagnose MS by differentiating 
between healthy mice, EAE-mice, and EAE-mice treated 
with fingolimod, a drug recently approved for MS therapy. 
Urine metabolites were evaluated by NMR spectroscopy 
using an experimental design that consisted of seven treat 
US 9,304,123 B2 
ment groups: control, saline, complete Freund's adjuvant 
(CFA), EAE, saline plus fingolimod, CFA plus fingolimod 
and EAE plus fingolimod. FIG.3 shows the one-dimensional 
(1D) H NMR spectra of urine obtained from healthy mice, 
EAE-mice, and EAE-mice treated with fingolimod. A set of 
NMR peaks (labeled B) are significantly increased in the 
spectra for healthy mice relative to diseased mice. Con 
versely, two sets of NMR peaks (labeled A and A') are 
increased in the diseased mice spectrum relative to healthy 
mice. These spectral differences correspond to a set of 
metabolites that are differentially up-regulated and down 
regulated in EAE-mice and are potential biomarkers for MS. 
Additionally, the NMR spectra for the other control groups, 
saline, Saline plus fingolimod or CFA plus fingolimod, were 
essentially identical to the NMR spectra for the healthy mice. 
It was next evaluated whether fingolimod would alter the 
metabolomic profile of EAE-mice, consistent with its pre 
dicted efficacy against MS. As expected, the urine metabo 
lites observed in the NMR spectra for the EAE mice treated 
with fingolimod resembled the NMR spectra for the healthy 
mice (FIG.3). The spectral region B suppressed in EAE mice 
has increased in intensity (labeled B"). Similarly, the spectral 
regions A and A' have disappeared in EAE-mice treated with 
fingolimod, shifting the metabolomics profiles towards the 
healthy mice. To further quantitate the differences in the 
metabolites obtained in healthy and EAE-mice, multivariate 
statistical analysis techniques were used. A 2D plot from an 
orthogonal partial least square discrete analysis (OPLS-DA) 
revealed distinct clusters between the two groups (FIG. 4A). 
As expected, control mice injected with saline, CFA and 
fingolimod clustered together with the healthy mice. Notably, 
the EAE mice treated with fingolimod were also clustered 
with the controls. These results were further corroborated by 
generating a metabolomics tree diagram (FIG. 4B). The high 
boot-strap numbers (>50) indicate the statistical relevance of 
each cluster or node. 
An S-plot from the OPLS-DA is shown in FIG. 5. Each 
point in the S-plot corresponds to a chemical shift range of 
0.025 ppm or, more relevant, to a specific metabolite. The 
point (metabolite) that significantly contributes to the class 
cluster separation in the 2D scores plot are found at the 
extremes (labeled) of the S-plot. The S-plot and NMR spectra 
were compared to verify the spectral contributions to the class 
separation between healthy and EAE mice. Points in the 
S-plot represented by triangles (A) were found to correlate 
with NMR peaks in the previously identified A, A, B and B' 
spectral regions in FIG. 3. These analyses validate the use of 
NMR spectroscopy technology to assess urine metabolites as 
indicators of disease progression in the EAE model. 
Urinary metabolites were further analyzed using 2D 'H-' 
C HSQC spectra obtained from urine samples pooled from a 
group of healthy or EAE mice. The use of pooled samples was 
necessary because of the low natural abundance of C-la 
beled metabolites. The 2D 'H-CHSQC spectra were com 
pared between the two groups to identify the differences in 
peak intensities. The NMR peaks were then assigned to 
metabolites using Human Metabolomic Databases (hmdb.ca 
on the World Wide Web). Metabolites are assigned based on 
minimizing the chemical shift differences between the 
experimental values reported herein and the values deposited 
in the database, and maximizing the number of matching 














or down-regulated in EAE-relative to healthy mice were plot 
ted (FIG. 6). The analysis revealed that 3-ureidopropionic 
acid (UDPA), guanidinoacetate (GA) and indoxyl sulfate 
(ISU) were significantly down-regulated in the EAE mice, 
thereby suggesting that any of these three metabolites can be 
used as markers of a neurological autoimmune disorder. 
Metformin, a drug used for diabetes mellitus, has been 
shown to attenuate EAE progression in animal models (Nath 
et al., 2009, J. Immunol., 182:8005-14). It was noted that a 
NMR peak (UN 2 in FIG. 6) appears to have a structure 
similar to metformin. It was postulated, therefore, that a met 
formin-like metabolite might play a role in MS. A second 
unknown aromatic metabolite also was observed, the concen 
tration of which was relatively higher in EAE as compared to 
healthy mice (FIG. 6). The detection of these structurally 
uncharacterized metabolites provides new insights as to the 




It has been demonstrated herein that the metabolite com 
position of urine samples differs between healthy and EAE 
mice. Several key metabolites also have been identified that 
are consistently down- or up-regulated in EAE-mice in com 
parison with controls. 
In addition, the metabolites can be used in the evaluation of 
in vivo efficacy of potential drug-leads and designing patient 
specific treatments. 
The NMR analysis of urine by NMR takes approximately 
10 minutes per sample and completely lacks any of the risks 
or side effects associated with the analysis of other biological 
samples, such as cerebrospinal fluid. 
The lack of cure for MS and its increasing prevalence 
amoung the population of young adults further emphasizes 
the need to identify reliable markers of disease progression. 
Thus, the NMR analysis of urine samples to evaluate the 
metabolites identified herein holds the promise of being an 
easy, fast, and safe diagnostic tool for MS. 
It is to be understood that, while the methods and compo 
sitions of matter have been described herein in conjunction 
with a number of different aspects, the foregoing description 
of the various aspects is intended to illustrate and not limit the 
scope of the methods and compositions of matter. Other 
aspects, advantages, and modifications are within the scope of 
the following claims. 
Disclosed are methods and compositions that can be used 
for, can be used in conjunction with, can be used in prepara 
tion for, or are products of the disclosed methods and com 
positions. These and other materials are disclosed herein, and 
it is understood that combinations, Subsets, interactions, 
groups, etc. of these methods and compositions are disclosed. 
That is, while specific reference to each various individual 
and collective combinations and permutations of these com 
positions and methods may not be explicitly disclosed, each is 
specifically contemplated and described herein. For example, 
if a particular composition of matter or a particular method is 
disclosed and discussed and a number of compositions or 
methods are discussed, each and every combination and per 
mutation of the compositions and the methods are specifically 
contemplated unless specifically indicated to the contrary. 
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Likewise, any Subset or combination of these is also specifi 
cally contemplated and disclosed. 
What is claimed is: 
1. A method of monitoring the progression of EAE in a 
rodent comprising: 
collecting a urine sample from a rodent having EAE; and 
determining the levels of one or more biomarkers in the 
rodent's urine, wherein the one or more biomarkers 
compromise 3-ureidopropionic acid; 
wherein an increase in the level of the one or more biom 
arkers in the rodent’s urine is indicative of the progres 
sion of EAE in the rodent. 
2. The method of claim 1, wherein the one or more biom 
arkers further comprise guanidinoacetate. 
3. The method of claim 1, wherein the one or more biom 
arkers further comprise indoxyl sulfate. 
4. The method of claim 1, wherein the one or more biom 
arkers further comprise guanidinoacetate and indoxyl Sulfate. 
5. The method of claim 1, wherein the levels of the one or 
more biomarkers are determined using an immunoassay, 
chromatography, spectroscopy or NMR. 
6. The method of claim 1, wherein the levels of the one or 
more biomarkers in the rodent’s urine are compared to the 
levels of the one or more biomarkers in a control rodent that 
does not suffer from EAE. 
7. The method of claim 1, wherein the levels of the one or 






8. A method of determining whether a compound is effec 
tive for ameliorating the symptoms of EAE in a rodent, com 
prising: 
collecting a first urine sample from a rodent having EAE; 
determining the levels of one or more biomarkers in the 
first urine sample, wherein the one or more biomarkers 
comprise 3-ureidopropionic acid; 
administering a compound to the rodent having EAE; 
collecting a second urine sample from the rodent having 
EAE; and 
determining the levels of the one or more of the biomarkers 
in the secondurine sample, 
wherein a decrease in the level of one or more biomarkers 
in the second urine sample relative to the first urine 
sample is indicative of a compound that is effective for 
ameliorating the symptoms of EAE in a rodent. 
9. The method of claim 8, wherein the one or more biom 
arkers further comprise guanidinoacetate. 
10. The method of claim8, wherein the one or more biom 
arkers further comprise indoxyl sulfate. 
11. The method of claim8, wherein the one or more biom 
arkers further comprise guanidinoacetate and indoxyl Sulfate. 
12. The method of claim 8, wherein the levels of the one or 
more biomarkers are determined using an immunoassay, 
chromatography, spectroscopy or NMR. 
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